Alize Pharma SAS
Records under this name other than patents Alize Pharma SAS holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Alize Pharma SAS
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,222,217 | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders Lapsed on the fee record Ended Jul 17, 2024 · From the USPTO record | Lapsed on the fee record | Ended Jul 17, 2024 | From the USPTO record |
| US 8,071,368 | Methods for promoting growth and survival of insulin-secreting cells Term ended Term ended Jan 28, 2023 · From the USPTO record | Term ended | Term ended Jan 28, 2023 | From the USPTO record |
| US 7,825,090 | Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance Lapsed on the fee record Ended Nov 2, 2022 · From the USPTO record | Lapsed on the fee record | Ended Nov 2, 2022 | From the USPTO record |
| US 7,666,833 | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof Lapsed on the fee record Ended Feb 23, 2022 · From the USPTO record | Lapsed on the fee record | Ended Feb 23, 2022 | From the USPTO record |
| US 8,476,408 | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease Lapsed on the fee record Ended Jul 2, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jul 2, 2021 | From the USPTO record |
| US 7,485,620 | Pharmaceutical Compositions Comprising Unacylated Ghrelin and Therapeutical Uses Thereof Lapsed on the fee record Ended Feb 3, 2021 · High confidence | Lapsed on the fee record | Ended Feb 3, 2021 | High confidence |
| US 9,550,821 | Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin Lapsed on the fee record Ended Jan 24, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jan 24, 2021 | From the USPTO record |
| US 8,318,664 | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity Lapsed on the fee record Ended Nov 27, 2020 · From the USPTO record | Lapsed on the fee record | Ended Nov 27, 2020 | From the USPTO record |